or
forgot password

A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia


Phase 1
18 Years
N/A
Open (Enrolling)
Both
Chronic Lymphocytic Leukemia

Thank you

Trial Information

A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia


Inclusion Criteria:



- Diagnosis of CLL

- CLL previously treated

- Hemoglobin >/= 10

- Platelets >/= 50,000

- Neutrophils >= 1,000 -

Exclusion Criteria:

- patients with brain mets

- patients with autoimmune disease

- patients on corticosteroids or immunosuppressants

- patients with uncontrolled intercurrent illness

- pregnant women

- HIV patients receiving combination anti-retroviral therapy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Brian Link, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UIHC

Authority:

United States: Food and Drug Administration

Study ID:

200402002

NCT ID:

NCT00233506

Start Date:

July 2004

Completion Date:

Related Keywords:

  • Chronic Lymphocytic Leukemia
  • CpG 7909
  • CLL
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid

Name

Location
University of Iowa Iowa City, Iowa  52242
Mayo Clinic Rochester, Minnesota  55905